Nancy L. Van Buren
Research Subjects
Nancy L. Van Buren has a total of 67 co-authors. Here are the top co-authors by number of shared publications:
- Alyssa Ziman
Department of Pathology and Laboratory Medicine David Geffen School of Medicine at UCLA Los Angeles California USA
2 shared publications Camille M. van Buskirk
Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology Mayo Clinic Rochester Minnesota USA
2 shared publications- Connie M. Westhoff
Immunohematology and Genomics Laboratory New York Blood Center New York New York USA
2 shared publications - James R. Stubbs
Department of Laboratory Medicine and Pathology, Mayo Clinic
2 shared publications Jed B. Gorlin
Division of New York Blood Center Innovative Blood Resources Saint Paul Minnesota USA
2 shared publications- Jed Gorlin
Physician Services New York Blood Center Enterprises New York New York USA
2 shared publications
Latest Publications
- 22 November 2024
- Published by Elsevier
- p. 355-358
Transfusion-Associated Dyspnea, Hypotensive Reactions, Metabolic and Other Acute Complications of Transfusion
- 22 November 2024
- Published by Elsevier
- p. 355-358
Transfusion-Associated Dyspnea, Hypotensive Reactions, Metabolic and Other Acute Complications of Transfusion
- 22 November 2024
- Published by Elsevier
- p. 257-264
Perinatal Transfusion Medicine and Hemolytic Disease of the Fetus and Newborn
- 22 November 2024
- Published by Elsevier
- p. 257-264
Perinatal Transfusion Medicine and Hemolytic Disease of the Fetus and Newborn
- 22 November 2024
- Published by Elsevier
- p. 265-273
Autoimmune Hemolytic Anemias
- 2 June 2023
- Published by Wiley in Transfusion
- Vol. 63 (7) , 1284-1289
Confronting the challenge of gender nonconforming donors: A blood center's three‐year experience
Background: Blood center organizations (BCOs) have traditionally offered two gender choices (male or female) on the donor history questionnaire (DHQ). Our BCO was one of the first in the United States to offer additional options on our DHQ to improve the experience for gender nonconforming donors.Study Design and Methods: Three years of data were analyzed from all blood donation visits between March 2019 and March 2022. Donors were stratified by gender categories and generation as follows: Gen Z, Millennial, Gen X, Boomers, and Silent. First time donor status, donor deferrals and infectious disease rates were evaluated for each category.Results: Donor gender makeup included 127,072 (99.78%) Male/Female (M/F) and 282 (0.22%) Trans/Other (T/O) donors. The return rate for first‐time donors was 36.75% for M/F donors compared to 33.84% for T/O donors. The generational breakdown of our T/O donors is 71.28% Gen Z, 21.99% Millennial, 3.19% Gen X, 3.55% Boomers and none from the Silent Generation. Comparing high risk DHQ deferrals, there were 719 (0.57%) M/F deferrals and 18 (6.38%) T/O deferrals. Disease marker testing resulted in 2314 (0.56%) deferrals of M/F donors compared to 2 (0.41%) T/O deferrals.Conclusion: Increased gender options on the DHQ allowing gender diverse self‐identification enhances inclusivity. Transgender and nonbinary individuals accounted for a minority of donors, most of whom are younger, and have a comparable return rate to M/F donors. Shifts in donor policies can ensure inclusivity of this diverse population and provide an opportunity to expand the base of eligible donors.
- 2 June 2023
- Published by Wiley in Transfusion
- Vol. 63 (7) , 1284-1289
Confronting the challenge of gender nonconforming donors: A blood center's three‐year experience
Background: Blood center organizations (BCOs) have traditionally offered two gender choices (male or female) on the donor history questionnaire (DHQ). Our BCO was one of the first in the United States to offer additional options on our DHQ to improve the experience for gender nonconforming donors.Study Design and Methods: Three years of data were analyzed from all blood donation visits between March 2019 and March 2022. Donors were stratified by gender categories and generation as follows: Gen Z, Millennial, Gen X, Boomers, and Silent. First time donor status, donor deferrals and infectious disease rates were evaluated for each category.Results: Donor gender makeup included 127,072 (99.78%) Male/Female (M/F) and 282 (0.22%) Trans/Other (T/O) donors. The return rate for first‐time donors was 36.75% for M/F donors compared to 33.84% for T/O donors. The generational breakdown of our T/O donors is 71.28% Gen Z, 21.99% Millennial, 3.19% Gen X, 3.55% Boomers and none from the Silent Generation. Comparing high risk DHQ deferrals, there were 719 (0.57%) M/F deferrals and 18 (6.38%) T/O deferrals. Disease marker testing resulted in 2314 (0.56%) deferrals of M/F donors compared to 2 (0.41%) T/O deferrals.Conclusion: Increased gender options on the DHQ allowing gender diverse self‐identification enhances inclusivity. Transgender and nonbinary individuals accounted for a minority of donors, most of whom are younger, and have a comparable return rate to M/F donors. Shifts in donor policies can ensure inclusivity of this diverse population and provide an opportunity to expand the base of eligible donors.
- 24 December 2022
- Published by Wiley in Transfusion
- Vol. 63 (3) , 552-563
Demographics of first‐time donors returning for donation during the pandemic: COVID‐19 convalescent plasma versus standard blood product donors
Background: Previous studies have demonstrated low first‐time donor return rates (DRR) following catastrophic events. Little is known, however, about the influence of demographic factors on the DRR of first‐time donors during the COVID‐19 pandemic, including the unique motivation of COVID‐19 convalescent plasma (CCP) donors as compared to non‐CCP donors.Study Design and Methods: Thirteen blood collection organizations submitted deidentified data from first‐time CCP and non‐CCP donors returning for regular (non‐CCP) donations during the pandemic. DRR was calculated as frequencies. Demographic factors associated with returning donors: race/ethnicity, gender, and generation (Gen Z: 19–24, Millennial: 25–40, Gen X: 41–56, and Boomer: ≥57 years old), within the CCP and non‐CCP first‐time cohorts were compared using chi‐square test at p < .05 statistical significance.Results: From March 2020 through December 2021, there were a total of 44,274 first‐time CCP and 980,201 first‐time non‐CCP donors. DRR were 14.6% (range 11.9%–43.3%) and 46.6% (range 10.0%–76.9%) for CCP and non‐CCP cohorts, respectively. Age over 40 years (Gen X and Boomers), female gender, and White race were each associated with higher return in both donor cohorts (p < .001). For the non‐CCP return donor cohort, the Millennial and Boomers were comparable.Conclusion: The findings demonstrate differences in returning donor trends between the two donor cohorts. The motivation of a first‐time CCP donor may be different than that of a non‐CCP donor. Further study to improve first‐time donor engagement would be worthwhile to expand the donor base with a focus on blood donor diversity emphasizing engagement of underrepresented minorities and younger donors.
- 24 December 2022
- Published by Wiley in Transfusion
- Vol. 63 (3) , 552-563
Demographics of first‐time donors returning for donation during the pandemic: COVID‐19 convalescent plasma versus standard blood product donors
Background: Previous studies have demonstrated low first‐time donor return rates (DRR) following catastrophic events. Little is known, however, about the influence of demographic factors on the DRR of first‐time donors during the COVID‐19 pandemic, including the unique motivation of COVID‐19 convalescent plasma (CCP) donors as compared to non‐CCP donors.Study Design and Methods: Thirteen blood collection organizations submitted deidentified data from first‐time CCP and non‐CCP donors returning for regular (non‐CCP) donations during the pandemic. DRR was calculated as frequencies. Demographic factors associated with returning donors: race/ethnicity, gender, and generation (Gen Z: 19–24, Millennial: 25–40, Gen X: 41–56, and Boomer: ≥57 years old), within the CCP and non‐CCP first‐time cohorts were compared using chi‐square test at p < .05 statistical significance.Results: From March 2020 through December 2021, there were a total of 44,274 first‐time CCP and 980,201 first‐time non‐CCP donors. DRR were 14.6% (range 11.9%–43.3%) and 46.6% (range 10.0%–76.9%) for CCP and non‐CCP cohorts, respectively. Age over 40 years (Gen X and Boomers), female gender, and White race were each associated with higher return in both donor cohorts (p < .001). For the non‐CCP return donor cohort, the Millennial and Boomers were comparable.Conclusion: The findings demonstrate differences in returning donor trends between the two donor cohorts. The motivation of a first‐time CCP donor may be different than that of a non‐CCP donor. Further study to improve first‐time donor engagement would be worthwhile to expand the donor base with a focus on blood donor diversity emphasizing engagement of underrepresented minorities and younger donors.
- 29 July 2022
- Published by Wiley in Transfusion
- Vol. 62 (9) , 1917-1922
YTGT: A new high‐prevalence antigen in the Yt blood group system in two unrelated Native Americans and transfusion management
Background: The Yt system consists of five antigens: antithetical Yta/Ytb and the high‐prevalence antigens YTEG, YTLI, and YTOT. We investigated a sample from a Native American (NA) female with post‐operative anemia and an unidentified antibody who developed rigors, tachycardia, and hypotension on transfusion of incompatible RBCs.Methods and Materials: Serologic testing methods included LISS, PEG, and IgG gel. Test RBCs were treated with papain, trypsin, alpha‐chymotrypsin, 2‐amino‐ethylisothiouronium, and dithiothreitol. Rare RBCs were tested, and inhibition studies were performed. DNA extracted from WBCs was used for Sanger sequencing.Results: Initial testing showed strong 3–4+ plasma reactivity with all panel cells at LISS IAT; auto control was negative. Positive reactions were observed with numerous rare RBCs except for PNH‐III, which lack GPI‐linked DO, Yt, CROM, JMH, and Emm. Enzyme sensitivity patterns suggest Yt specificity, and soluble recombinant srYt neutralized reactivity. ACHE sequencing revealed YT*A/A genotype but with a homozygous change in exon 2, c.290A>G (p.Gln97Arg). Antibody reactivity was reminiscent of that seen in an unrelated NA male investigated previously. His RBCs were nonreactive with her plasma. ACHE carried the same c.290G/G change.Conclusion: Two unrelated NA patients were found to have an antibody to a new high‐prevalence Yt antigen, designated YTGT (YT6), associated with a clinically significant transfusion reaction. Identification of the specificity relied on enzyme sensitivity, use of PNH‐III RBCs, neutralization using soluble recombinant Yt, and the finding of a novel change in ACHE, c.290A>G (p.Gln97Arg), designated YT*01.‐06. IVIG and steroids were used to mitigate further reactions to transfusion.
- 29 July 2022
- Published by Wiley in Transfusion
- Vol. 62 (9) , 1917-1922
YTGT: A new high‐prevalence antigen in the Yt blood group system in two unrelated Native Americans and transfusion management
Background: The Yt system consists of five antigens: antithetical Yta/Ytb and the high‐prevalence antigens YTEG, YTLI, and YTOT. We investigated a sample from a Native American (NA) female with post‐operative anemia and an unidentified antibody who developed rigors, tachycardia, and hypotension on transfusion of incompatible RBCs.Methods and Materials: Serologic testing methods included LISS, PEG, and IgG gel. Test RBCs were treated with papain, trypsin, alpha‐chymotrypsin, 2‐amino‐ethylisothiouronium, and dithiothreitol. Rare RBCs were tested, and inhibition studies were performed. DNA extracted from WBCs was used for Sanger sequencing.Results: Initial testing showed strong 3–4+ plasma reactivity with all panel cells at LISS IAT; auto control was negative. Positive reactions were observed with numerous rare RBCs except for PNH‐III, which lack GPI‐linked DO, Yt, CROM, JMH, and Emm. Enzyme sensitivity patterns suggest Yt specificity, and soluble recombinant srYt neutralized reactivity. ACHE sequencing revealed YT*A/A genotype but with a homozygous change in exon 2, c.290A>G (p.Gln97Arg). Antibody reactivity was reminiscent of that seen in an unrelated NA male investigated previously. His RBCs were nonreactive with her plasma. ACHE carried the same c.290G/G change.Conclusion: Two unrelated NA patients were found to have an antibody to a new high‐prevalence Yt antigen, designated YTGT (YT6), associated with a clinically significant transfusion reaction. Identification of the specificity relied on enzyme sensitivity, use of PNH‐III RBCs, neutralization using soluble recombinant Yt, and the finding of a novel change in ACHE, c.290A>G (p.Gln97Arg), designated YT*01.‐06. IVIG and steroids were used to mitigate further reactions to transfusion.
- Open Access
- 6 July 2021
- Published by Wiley in Transfusion
- Vol. 61 (9) , 2668-2676
The safety of COVID‐19 convalescent plasma donation: A multi‐institutional donor hemovigilance study
Background Although the safety and therapeutic efficacy of COVID-19 convalescent plasma (CCP) has been extensively evaluated, the safety of CCP donation has not been explored in a multi-institutional context. Study design and methods Nine blood collection organizations (BCOs) participated in a multi-institutional donor hemovigilance effort to assess the safety of CCP donation. Donor adverse events (DAEs) were defined according to the Standard for Surveillance of Complications Related to Blood Donation, and severity was assessed using the severity grading tool. Multivariate analysis was performed to determine attributes associated with DAE severity. Results The overall DAE rate was 37.7 per 1000 donations. Repeat apheresis and apheresis-naïve donors experienced adverse event rates of 19.9 and 49.8 per 1000 donations, respectively. Female donors contributed 51.9% of CCP donations with a DAE rate of 49.4 per 1000 donations. The DAE rate for male donors was 27.4 per 1000 donations. Vasovagal reactions accounted for over half of all reported DAEs (51.1%). After adjustment, volume of CCP donated was associated with vasovagal reaction severity (odds ratio [OR] 6.5, 95% confidence interval [CI] 2.5–17.1). Donor age and donation history were also associated with DAE severity. Considerable differences in DAE types and rates were observed across the participating BCOs despite the use of standardized hemovigilance definitions. Conclusion The safety of CCP donation appears comparable to that of conventional apheresis plasma donation with similar associated risk factors for DAE types and severity.
- 6 July 2021
- Published by Wiley in Transfusion
- Vol. 61 (9) , 2668-2676
Open AccessThe safety of COVID‐19 convalescent plasma donation: A multi‐institutional donor hemovigilance study
Background Although the safety and therapeutic efficacy of COVID-19 convalescent plasma (CCP) has been extensively evaluated, the safety of CCP donation has not been explored in a multi-institutional context. Study design and methods Nine blood collection organizations (BCOs) participated in a multi-institutional donor hemovigilance effort to assess the safety of CCP donation. Donor adverse events (DAEs) were defined according to the Standard for Surveillance of Complications Related to Blood Donation, and severity was assessed using the severity grading tool. Multivariate analysis was performed to determine attributes associated with DAE severity. Results The overall DAE rate was 37.7 per 1000 donations. Repeat apheresis and apheresis-naïve donors experienced adverse event rates of 19.9 and 49.8 per 1000 donations, respectively. Female donors contributed 51.9% of CCP donations with a DAE rate of 49.4 per 1000 donations. The DAE rate for male donors was 27.4 per 1000 donations. Vasovagal reactions accounted for over half of all reported DAEs (51.1%). After adjustment, volume of CCP donated was associated with vasovagal reaction severity (odds ratio [OR] 6.5, 95% confidence interval [CI] 2.5–17.1). Donor age and donation history were also associated with DAE severity. Considerable differences in DAE types and rates were observed across the participating BCOs despite the use of standardized hemovigilance definitions. Conclusion The safety of CCP donation appears comparable to that of conventional apheresis plasma donation with similar associated risk factors for DAE types and severity.
- Open Access
- 25 May 2021
- Published by Wiley in Transfusion
- Vol. 61 (8) , 2250-2254
The effect of the SARS‐CoV‐2 pandemic and civil unrest on massive transfusion protocol activations in Minneapolis 2020
Background: The year 2020 presented the transfusion community with unprecedented events and challenges, including the ongoing SARS‐CoV‐2 (COVID‐19) pandemic, and more recently by civil unrest, following the death of George Floyd in late May of 2020. As a level 1 trauma center located in Minneapolis, Minnesota, Hennepin Healthcare (HCMC) offers a unique perspective into the changes in massive transfusion protocol (MTP) activations and usage during this tumultuous period. This may provide insight for addressing similar future events.Study design and methods: MTP logs from March 2020 to August 2020 were compared to logs from March to August 2019. The data were de‐identified, and MTP activations and component usage were categorized by activation reason. These categories were compared across the 2‐year period to examine the impact of COVID‐19, including stay‐at‐home orders, and civil unrest.Results: For the examined 6 months of the year 2020, there were a total of 140 MTP activations, compared to 143 in 2019. There were more activations for violent trauma (VT) in 2020 than 2019 (44 vs. 32). This increase in activations for VT was offset by a decrease in non‐trauma activations (54 vs. 66). There was a significant increase in the number of components used in VT activations.Discussion: During 2020, the initial mild decrease in MTP activations was followed by a dramatic increase in the number of activations and component usage for VT in June and July of that year.
- 25 May 2021
- Published by Wiley in Transfusion
- Vol. 61 (8) , 2250-2254
Open AccessThe effect of the SARS‐CoV‐2 pandemic and civil unrest on massive transfusion protocol activations in Minneapolis 2020
Background: The year 2020 presented the transfusion community with unprecedented events and challenges, including the ongoing SARS‐CoV‐2 (COVID‐19) pandemic, and more recently by civil unrest, following the death of George Floyd in late May of 2020. As a level 1 trauma center located in Minneapolis, Minnesota, Hennepin Healthcare (HCMC) offers a unique perspective into the changes in massive transfusion protocol (MTP) activations and usage during this tumultuous period. This may provide insight for addressing similar future events.Study design and methods: MTP logs from March 2020 to August 2020 were compared to logs from March to August 2019. The data were de‐identified, and MTP activations and component usage were categorized by activation reason. These categories were compared across the 2‐year period to examine the impact of COVID‐19, including stay‐at‐home orders, and civil unrest.Results: For the examined 6 months of the year 2020, there were a total of 140 MTP activations, compared to 143 in 2019. There were more activations for violent trauma (VT) in 2020 than 2019 (44 vs. 32). This increase in activations for VT was offset by a decrease in non‐trauma activations (54 vs. 66). There was a significant increase in the number of components used in VT activations.Discussion: During 2020, the initial mild decrease in MTP activations was followed by a dramatic increase in the number of activations and component usage for VT in June and July of that year.
- 5 March 2021
- Published by Wiley in Transfusion
- Vol. 61 (6) , 1780-1788
Frequency of rare, serious donor reactions: International perspective
Background: Severe blood donor adverse events are rare, but due to their rarity studying them can be difficult. To get an accurate estimate of their frequency and rate in the donor population it may be necessary to combine donation data across countries.Study Design and Methods: International blood collection organizations (BCOs) provided data on rare/severe donor reactions as well as denominator information for their donor populations from 2015 to 2017. Donor reactions were classified using standardized definitions.Results: BCOs from six countries provided reaction data for more than 22 million donations. A total of 480 rare reactions were reported of which 76.7% were imputed as definite and 11% probable. Rates of rare reactions were higher in females and first‐time donors. Systemic rare reactions were the most common reaction type, accounting for over three quarters of reactions reported. Of systemic reactions, vasovagal reactions with loss of consciousness and injury or off‐site (n = 350) made up the majority and occurred 1.53 per 100,000 donations. For the 22.3% that were localized reactions, the majority of these were cellulitis (n = 71, 0.31 per 100,000 donations) followed by deep venous thrombosis (n = 21, 0.09 per 100,000 donations).Conclusion: Pulling together data from multiple BCOs across countries allows for a better understanding of rare reactions, such as vasovagal reaction with injury or cellulitis, and for generating a reliable incidence rate for air embolism or compartment syndrome. However, gaps remain due to missing elements such as unknown donor status or location of reaction.
- 5 March 2021
- Published by Wiley in Transfusion
- Vol. 61 (6) , 1780-1788
Frequency of rare, serious donor reactions: International perspective
Background: Severe blood donor adverse events are rare, but due to their rarity studying them can be difficult. To get an accurate estimate of their frequency and rate in the donor population it may be necessary to combine donation data across countries.Study Design and Methods: International blood collection organizations (BCOs) provided data on rare/severe donor reactions as well as denominator information for their donor populations from 2015 to 2017. Donor reactions were classified using standardized definitions.Results: BCOs from six countries provided reaction data for more than 22 million donations. A total of 480 rare reactions were reported of which 76.7% were imputed as definite and 11% probable. Rates of rare reactions were higher in females and first‐time donors. Systemic rare reactions were the most common reaction type, accounting for over three quarters of reactions reported. Of systemic reactions, vasovagal reactions with loss of consciousness and injury or off‐site (n = 350) made up the majority and occurred 1.53 per 100,000 donations. For the 22.3% that were localized reactions, the majority of these were cellulitis (n = 71, 0.31 per 100,000 donations) followed by deep venous thrombosis (n = 21, 0.09 per 100,000 donations).Conclusion: Pulling together data from multiple BCOs across countries allows for a better understanding of rare reactions, such as vasovagal reaction with injury or cellulitis, and for generating a reliable incidence rate for air embolism or compartment syndrome. However, gaps remain due to missing elements such as unknown donor status or location of reaction.
- 5 March 2020
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 154 (1) , 33-37
Therapeutic Phlebotomy for Testosterone-Induced Polycythemia
Objectives: To evaluate therapeutic phlebotomy (TP) requests for testosterone replacement therapy (TRT) and to highlight the impact to a blood center (BC) or service that provides TP for individuals on TRT. Methods: Review of TP requests for individuals on TRT at our BC over a 3-year period from 2014 through 2016, as well as the total number of TP collections. Results: Total TPs during 2014, 2015, and 2016 were 475, 500, and 569, respectively. Annual TP collections for patients on TRT were 193, 212, and 239, respectively. TRT patients with TP orders increased 71.4% during this period. After discontinuation of TP services for TRT at our BC, 32% continued to donate as volunteer blood donors at our BC. Conclusions: Our BC observed increased TP requests for patients on TRT from 2014 through 2016. Our findings suggest that individuals on TRT may be presenting to BCs as volunteer blood donors to avoid charges for TP.
- 5 March 2020
- Published by Oxford University Press (OUP) in American Journal of Clinical Pathology
- Vol. 154 (1) , 33-37
Therapeutic Phlebotomy for Testosterone-Induced Polycythemia
Objectives: To evaluate therapeutic phlebotomy (TP) requests for testosterone replacement therapy (TRT) and to highlight the impact to a blood center (BC) or service that provides TP for individuals on TRT. Methods: Review of TP requests for individuals on TRT at our BC over a 3-year period from 2014 through 2016, as well as the total number of TP collections. Results: Total TPs during 2014, 2015, and 2016 were 475, 500, and 569, respectively. Annual TP collections for patients on TRT were 193, 212, and 239, respectively. TRT patients with TP orders increased 71.4% during this period. After discontinuation of TP services for TRT at our BC, 32% continued to donate as volunteer blood donors at our BC. Conclusions: Our BC observed increased TP requests for patients on TRT from 2014 through 2016. Our findings suggest that individuals on TRT may be presenting to BCs as volunteer blood donors to avoid charges for TP.